Welcome to our dedicated page for Pmv Pharmaceuticals news (Ticker: PMVP), a resource for investors and traders seeking the latest updates and insights on Pmv Pharmaceuticals stock.
PMV Pharmaceuticals, Inc. (PMV Pharma; Nasdaq: PMVP) is a precision oncology clinical-stage company focused on small molecule, tumor-agnostic therapies targeting p53. News about PMV Pharma centers on the clinical and regulatory progress of its lead investigational therapy, rezatapopt (PC14586), and the advancement of its p53-focused pipeline.
Readers following PMVP news can expect frequent updates on the PYNNACLE Phase 1/2 clinical trial, which evaluates rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. Company announcements describe interim and updated Phase 2 data, including overall response rates and duration of response across cohorts such as ovarian, lung, breast, endometrial cancers, and other solid tumors with TP53 Y220C and KRAS wild-type status.
PMV Pharma’s news flow also includes financial results and corporate highlights, typically released quarterly and annually. These updates summarize research and development spending, general and administrative expenses, cash, cash equivalents, and marketable securities, and provide commentary on expected cash runway to support ongoing clinical development.
Additional news items cover scientific presentations and collaborations, such as oral and poster presentations at oncology and pharmacology conferences, investigator-initiated studies in AML/MDS, and partnerships related to companion diagnostics. Investors and observers can use this page to track rezatapopt’s development, regulatory interactions, and PMV Pharma’s broader precision oncology strategy. For those monitoring PMVP, regularly reviewing this news feed provides a consolidated view of clinical milestones, data disclosures, and corporate developments.
PMV Pharmaceuticals (Nasdaq: PMVP) reported full-year 2025 results and clinical progress for rezatapopt. Key clinical highlights include FDA Orphan Drug Designation (Mar 2, 2026), NEJM publication of Phase 1 data, Phase 2 PYNNACLE activity with ovarian cohort ORRs up to 50% post-cutoff, and an NDA planned for Q1 2027. Financials: $112.9M cash and marketable securities as of Dec 31, 2025, net loss of $77.7M, and net cash used in operations of $73.6M, providing runway to end of Q2 2027.
PMV Pharma (Nasdaq: PMVP) reported that Phase 1, first-in-human rezatapopt data were published in the New England Journal of Medicine on Feb 26, 2026. The Phase 1 portion enrolled 77 heavily pretreated TP53 Y220C-mutant patients, showed objective responses across tumor types, supported an RP2D, and demonstrated safety, pharmacokinetics, and biomarker evidence of selective Y220C p53 reactivation. The company plans a New Drug Application submission in Q1 2027 for platinum-resistant/refractory ovarian cancer and reported Phase 2 interim ORR of 34% overall and 46% in ovarian cancer (data cutoff Sep 4, 2025).
PMV Pharmaceuticals (Nasdaq: PMVP) reported third-quarter 2025 results and clinical updates on rezatapopt from the Phase 2 pivotal PYNNACLE study presented at the 2025 AACR-NCI-EORTC conference on October 24, 2025.
Key clinical data: 34% ORR (35/103) across evaluable patients, 46% ORR in the ovarian cohort (22/48) with one confirmed complete response and median duration of response of 8.0 months in ovarian patients. Median time to response across cohorts was 1.3 months. The company plans an NDA submission for platinum-resistant/refractory ovarian cancer in Q1 2027.
Financials: cash, equivalents, and marketable securities of $129.3M as of September 30, 2025, providing expected runway to end of Q1 2027. Net cash used in operations was $56.4M for the nine months ended September 30, 2025.
PMV Pharmaceuticals (Nasdaq: PMVP) reported updated Phase 2 PYNNACLE monotherapy data for rezatapopt (TP53 Y220C) with a 34% ORR across 103 evaluable patients and median duration of response of 7.6 months (data cutoff Sept 4, 2025). Confirmed responses appeared in eight tumor types including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary cancer.
The ovarian cohort showed a 46% ORR (22/48) with median duration of response 8.0 months. Safety was mostly Grade 1–2; Grade 3 TRAEs ≤6% and drug discontinuations due to TRAEs were 3.6%. An NDA for platinum-resistant/refractory ovarian cancer is planned for Q1 2027.
PMV Pharmaceuticals (NASDAQ: PMVP) will present initial clinical data for rezatapopt at the AACR-NCI-EORTC conference in Boston on October 22–26, 2025. An oral presentation will report an initial analysis of the pivotal PYNNACLE Phase 2 trial in patients with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation on Friday, October 24 at 10:00–11:40 AM ET, presented by Dr. Alison M. Schram.
Two poster presentations will follow: the PYNNACLE initial analysis on Friday, October 24 (12:30–4:00 PM ET, Poster Session B, Exhibit Hall D) and a real-world natural history and prognostic study of TP53 Y220C on Saturday, October 25 (12:30–4:00 PM ET, Poster Session C, Exhibit Hall D).
PMV Pharmaceuticals (NASDAQ:PMVP) announced promising interim data from its Phase 2 PYNNACLE trial evaluating rezatapopt in patients with TP53 Y220C-mutated advanced solid tumors. The trial demonstrated a 33% overall response rate (ORR) across 97 evaluable patients, with confirmed responses in eight different tumor types.
Key highlights include a 43% ORR in ovarian cancer patients with 7.6 months median duration of response. The safety profile showed mostly Grade 1-2 treatment-related adverse events, with a low 3.7% discontinuation rate. Following FDA feedback, PMV plans to enroll an additional 20-25 platinum resistant/refractory ovarian cancer patients and submit a New Drug Application (NDA) in Q1 2027.
PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, has announced its Q2 2025 financial results and will host an investor webinar on September 10, 2025 to review interim analysis data from the Phase 2 PYNNACLE clinical trial. The analysis will include data from approximately 65 patients with at least 18 weeks of follow-up, with about 45% in the ovarian cancer cohort.
The company reported $148.3 million in cash and equivalents as of June 30, 2025, providing runway through 2026. Q2 2025 net loss was $21.2 million, compared to $1.2 million in Q2 2024. R&D expenses increased to $18.4 million, while G&A expenses decreased to $4.5 million.
PMV Pharmaceuticals (PMVP), a precision oncology company focused on developing small molecule, tumor-agnostic therapies targeting p53, has announced its participation in two upcoming investor conferences. The company's management, including CEO David H. Mack and Chief Development Officer Deepika Jalota, will present at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 11:30 AM EDT, and the Jefferies Global Healthcare Conference on June 5, 2025, at 3:45 PM EDT. Both presentations will be available via live audio webcast, with replays accessible for 90 days afterward.
PMV Pharmaceuticals (PMVP) has reported its Q1 2025 financial results and provided updates on its PYNNACLE clinical trial for rezatapopt. The company plans to release interim analysis data from approximately 50 patients in mid-2025, with 40% from the ovarian cancer cohort. Financially, PMV ended Q1 with $165.8 million in cash and equivalents, expecting runway through 2026.
The company reported a net loss of $17.5 million for Q1 2025, compared to $15.3 million in Q1 2024. R&D expenses increased to $17.4 million from $13.2 million year-over-year, while G&A expenses decreased to $4.1 million from $5.0 million. Net cash used in operations was $18.3 million for Q1 2025.
PMV Pharmaceuticals (PMVP) reported its full year 2024 financial results, highlighting progress in its PYNNACLE clinical trial for rezatapopt. The company ended 2024 with $183.3 million in cash and equivalents, providing runway through 2026.
Key developments include:
- Over 90% of sites activated for Phase 2 PYNNACLE trial across global regions
- Interim analysis data expected mid-2025
- New Phase 1b study launched with MD Anderson Cancer Center
- Net loss of $58.7 million in 2024, improved from $69.0 million in 2023
- R&D expenses increased to $58.5 million from $55.9 million
The PYNNACLE Phase 1 trial showed promising results with 7 confirmed partial responses in ovarian cancer patients and 3 in breast cancer patients. However, the company discontinued the combination arm with KEYTRUDA® due to insufficient clinical benefit.